Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ipatasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ipatasertib (RG-7440/GDC-0068) is under development for the treatment of metastatic solid tumors including advanced or metastatic HER2-positive breast cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, castration-resistant prostate cancer in previously untreated patients and also patients treated with docetaxel chemotherapy, metastatic and hormone receptor-positive, HER2-negative breast cancer, glioblastoma mulitforme, melanoma, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The drug candidate is administered orally in the form of tablets and capsules. It is a small molecule with antineoplastic activity. Ipatasertib targets the serine/threonine protein kinase Akt (protein kinase B). It was also under development for neoadjuvant triple negative breast cancer, endometrial cancer and prostate cancer.
Genentech USA overview
Genentech USA (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. Its pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International, Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.
For a complete picture of Ipatasertib’s drug-specific PTSR and LoA scores, buy the report here.